Nexthera Capital as of March 31, 2018
Portfolio Holdings for Nexthera Capital
Nexthera Capital holds 39 positions in its portfolio as reported in the March 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 28.9 | $176M | 2.0M | 87.73 | |
| Allergan | 6.9 | $42M | 249k | 168.29 | |
| BioMarin Pharmaceutical (BMRN) | 4.9 | $30M | 367k | 81.07 | |
| Bristol Myers Squibb (BMY) | 3.6 | $22M | 342k | 63.25 | |
| Shire | 3.4 | $21M | 140k | 149.39 | |
| Insmed (INSM) | 3.4 | $21M | 919k | 22.52 | |
| Seattle Genetics | 3.1 | $19M | 363k | 52.34 | |
| Corcept Therapeutics Incorporated (CORT) | 2.8 | $17M | 1.0M | 16.45 | |
| AstraZeneca (AZN) | 2.8 | $17M | 484k | 34.97 | |
| Immunomedics | 2.6 | $16M | 1.1M | 14.61 | |
| Dova Pharmaceuticals | 2.5 | $15M | 568k | 27.12 | |
| Global Blood Therapeutics In | 2.5 | $15M | 315k | 48.30 | |
| Sangamo Biosciences (SGMO) | 2.5 | $15M | 786k | 19.00 | |
| Pacira Pharmaceuticals (PCRX) | 2.5 | $15M | 479k | 31.15 | |
| Catalyst Biosciences | 2.3 | $14M | 539k | 25.80 | |
| Clovis Oncology | 2.1 | $13M | 243k | 52.80 | |
| Sage Therapeutics (SAGE) | 2.1 | $13M | 78k | 161.07 | |
| Heron Therapeutics (HRTX) | 1.9 | $11M | 409k | 27.60 | |
| Cymabay Therapeutics | 1.8 | $11M | 853k | 12.99 | |
| Mylan Nv | 1.8 | $11M | 261k | 41.17 | |
| Cellectis S A (CLLS) | 1.7 | $11M | 333k | 31.51 | |
| Akorn | 1.6 | $9.4M | 505k | 18.71 | |
| D Stemline Therapeutics | 1.3 | $8.0M | 524k | 15.30 | |
| Arrowhead Pharmaceuticals (ARWR) | 1.3 | $8.0M | 1.1M | 7.21 | |
| Fibrogen (FGEN) | 1.1 | $7.0M | 151k | 46.20 | |
| Kura Oncology (KURA) | 1.1 | $6.6M | 352k | 18.75 | |
| Sol Gel Technologies (SLGL) | 0.9 | $5.3M | 518k | 10.30 | |
| Abeona Therapeutics | 0.9 | $5.3M | 370k | 14.35 | |
| Perrigo Company (PRGO) | 0.8 | $4.6M | 56k | 83.34 | |
| Cara Therapeutics (CARA) | 0.7 | $4.3M | 351k | 12.38 | |
| Madrigal Pharmaceuticals (MDGL) | 0.7 | $4.2M | 36k | 116.79 | |
| Oncosec Med | 0.6 | $3.9M | 2.1M | 1.88 | |
| Newlink Genetics Corporation | 0.6 | $3.6M | 500k | 7.25 | |
| Zosano Pharma Corp | 0.6 | $3.5M | 700k | 5.04 | |
| Zafgen | 0.5 | $3.0M | 402k | 7.45 | |
| Adverum Biotechnologies | 0.5 | $2.9M | 501k | 5.80 | |
| Menlo Therapeutics | 0.5 | $2.8M | 74k | 37.58 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.9M | 379k | 4.90 | |
| Homology Medicines | 0.0 | $243k | 13k | 18.69 |
